B ant T cell epitope prediction program
EpiQuest® is a software suite that has been primarily designed to predict and evaluate B and T epitopes in silico. This set of programs allows the user to detect and to predict the immunodominance (relative strength), complexity (uniqueness), evolutionary stability, potential for mutation and other parameters of B and T-epitopes.
It has been created for academic individuals and companies involved in the design of new specific antibodies, neutralizing antibodies, diagnostic immunoassays, B and T - vaccines.
News & Updates
The note explains and illustrates by real-life example how to choose the most immunogenic epitopes from a series of sequences selected according to some other criteria
New technical note has been published in the How To section:
History Behind The Software
EpiQuest began almost 10 years ago. Historically, Aptum Biologics and its predecessors have been involved in antibody development for their own programs, as well as custom antibodies. Our experience has clearly demonstrated that existing epitope prediction software has numerous limitations. While it can sometimes predict specific B-epitopes in protein sequences, most existing approaches are incapable of predicting the immunodominance of the epitope. Following the successful development of software for B-epitope prediction, we applied the same approach to create algorithms for characterizing other features of B-epitopes and CTL epitopes.
Unique Algorithms
EpiQuest is built upon unique algorithms developed by the informatics division of Aptum Biologics Ltd, a British biotechnology company. The program has been trained and evaluated using a distinct set of peptide epitopes employed by the company for antibody development. Over the years, these epitopes have been fully characterized in terms of their immunogenicity and other properties. Presently, EpiQuest stands out as the most accurate program for detecting linear epitopes within protein primary sequences and assessing their relative strength. Further details about the algorithms can be found in the respective sections of the particular program.
Layout & Presentation of the Results
EpiQuest enables users to save graphical results in high-resolution formats suitable for publication and presentations. Additionally, all tabular results can be exported for use in office and presentation programs, such as MS Office and others. The software also facilitates the simultaneous performance of multiple analyses, with results presented in the same graphical and tabular output.
Awards
In recent years, the software has received awards from several business and biotech journals, such as Global Health and Pharma (2020, 2021), for innovation in Bioinformatics and Antibody Development.
Customers
The EpiQuest Suite, now in version 4, has been tailored for both academic and business customers. It is accessible via subscription as online software hosted on secure servers, easily reachable through Chrome-based or Mozilla web browsers.
Primarily designed for researchers engaged in antibody development, studies of humoral and cytotoxic immune responses, and the development of diagnostic assays for viral and bacterial antigens, disease markers, specific antibody responses, and vaccines.
Some of our esteemed customers include:
Updates & New Programs
EpiQuest Suite is constantly developing software, and we regularly release updates, new tolls and discuss new applications.
Never miss the releases of new programs or protocols for particular tasks by adding your name to our mailing list
EpiQuest Suite and site www.epiquest.co.uk belongs to Aptum Biologics Ltd.
EpiQuest® is a registered Trademark of Aptum Biologics Ltd.
© 2018, 2020, 2021 Aptum Biologics Ltd.